(Q35810472)

10 August 2017

1 reference

title

Emtricitabine (FTC) for the treatment of HIV infection (English)

1 reference

10 August 2017

1 reference

ChEBI release 2020-05-28

Nelson M

1

1 reference

10 August 2017

Schiavone M

series ordinal

2

1 reference

10 August 2017

publication date

1 May 2004

1 reference

International Journal of Clinical Practice

10 August 2017

published in

1 reference

10 August 2017

volume

58

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

504-510

1 reference

Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1368-5031.2004.00100.X

Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1368-5031.2004.00100.X

The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1368-5031.2004.00100.X

Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1368-5031.2004.00100.X

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1368-5031.2004.00100.X

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1368-5031.2004.00100.X

Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1368-5031.2004.00100.X

Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1368-5031.2004.00100.X

10.1111/J.1368-5031.2004.00100.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference